Ruffena Capital
71-75 Shelton Street, London, WC2H 9JQ, United Kingdom
Overview
Established in 2013, Ruffena Capital has evolved to become a boutique private equity advisory business with its own investment platform - focused on raising true growth capital or alternative finance, typically in the £2-10m range for its clients. Ruffena’s investors are largely a private audience of experienced UK and international investors, funds, family offices and certain wealth managers, who prefer established, highly tangible opportunities that can demonstrate the ability to scale and generate returns. Ruffena secured or advised upon over £42m going into client projects over the 2016-17 financial year. In the current year this has risen significantly and Ruffena has also had two clients IPO and one full exit in 2017-18. Ruffena does take on some earlier stage projects, however they must emphatically demonstrate thorough planning; tangible commercial potential; and a workable investment proposition.
- Total investments
- 1
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 3
Sector focus
- Advice
- Finance
- Financial Services
Investment portfolio
- Lightpoint Medical
Participated · Series A · Dec 2014
Lightpoint Medical develops intraoperative imaging products, notably a robotic laparoscopic probe designed to detect cancer in real time and the LightPath® Imaging System. The LightPath system has already achieved commercial sales throughout Europe. The laparoscopic probe is intended to bring real-time cancer detection to minimally invasive and robotic surgery to improve tissue-sparing and clinical outcomes. The company will use new funding to commercialise the laparoscopic probe and support commercial growth of the LightPath system. It has secured a £5 million financing and previously raised more than £3 million in grant funding from the Horizon 2020 SME Instrument and Innovate UK. Management says the funds will prepare the company for commercial scale-up and a commercial launch of the laparoscopic probe. Lightpoint Medical, based in Rickmansworth, United Kingdom and Cambridge, Massachusetts, develops the EnLight™ fiberscope system that uses molecular imaging to reveal microscopic cancer deposits. The technology is intended to enable surgeons to identify cancerous tissue during procedures. The company will use the awarded funds to support clinical trials of EnLight™ in lymph node cancer and a range of gynecologic cancers at Memorial Sloan Kettering Cancer Center (MSK). Lightpoint will collaborate on the research with MSK’s Drs. Jan Grimm and Nadeem Abu-Rustum. The company is led by Founder and CEO Dr. David Tuch and is backed by business angels and other private investors. Lightpoint Medical develops surgical imaging technologies, including its lead products LightPath™ and EnLight™, to help surgeons detect cancer in real time and reduce the need for repeat operations. The company has clinical trials underway in breast, prostate and stomach cancer. Led by CEO Dr David Tuch, Lightpoint is UK-based and completed a Series A raise of £2m ($3.1m). The company intends to use the funds to bring LightPath and EnLight to the US and European markets in 2015. Its technology is positioned for intraoperative cancer detection to improve surgical outcomes and reduce follow-up procedures. Lightpoint Medical is a Rickmansworth, UK–based developer of innovative imaging technologies for cancer surgery. Founded in 2012 by Dr David Tuch, the company is developing a novel molecular imaging technology based on Cerenkov luminescence imaging. The technology is intended to help surgeons detect cancer in real time during surgery, providing more accurate treatment while sparing healthy tissue. In June 2013 the company raised £175K (approximately $270K) in seed funding. The round involved a mix of institutional and angel investors led by Oxford Technology Management.